Related Experiment Video
Updated: Sep 24, 2025
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
14.9K
An integrated approach to cardioprotection in lymphomas
Maja V Maraldo1, Mario Levis1, Alessandro Andreis2
1Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
The Lancet. Haematology
|May 5, 2022
Summary
Long-term survival in lymphoma patients hinges on managing treatment toxicity, particularly cardiotoxicity. This review explores mechanisms, clinical data, and cardioprotection strategies for lymphoma patients, emphasizing personalized follow-up and early detection.
Area of Science:
- Cardio-oncology
- Hematology
- Oncology
Background:
- Malignant lymphomas pose significant risks of acute and late treatment-related toxicity, impacting survival and quality of life.
- Cardiotoxicity is a major concern in lymphoma treatment, affecting long-term outcomes.
- Advances in chemotherapy and radiation therapy, alongside new drug introductions, necessitate a deeper understanding of cardiovascular risks.
Purpose of the Study:
- To summarize mechanisms of treatment-related cardiac injury in lymphoma patients.
- To review available clinical data and protocols for optimizing cardioprotection.
- To discuss research strategies for understanding drug- and radiation-induced cardiac toxicity and highlight personalized follow-up approaches.
Main Methods:
- Literature review of mechanisms of treatment-related cardiac injury.
- Analysis of clinical data and existing cardioprotection protocols for lymphomas.
- Discussion of ongoing research into molecular mechanisms of toxicity.
Main Results:
- Chemotherapy and radiotherapy for lymphomas can cause significant acute and late cardiotoxicity.
- New therapeutic agents introduce novel cardiotoxicity risks.
- Current understanding of cardiovascular disease associated with lymphoma treatment has advanced, but gaps remain.
Conclusions:
- Optimizing cardioprotection in lymphoma patients requires a comprehensive approach.
- Personalized follow-up, including biomarkers and novel diagnostic tests, is crucial for early detection of cardiotoxicity.
- The multidisciplinary cardio-oncology team plays a vital role in managing cardiac risks in lymphoma survivors.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
48
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
48
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:29Cardiomyopathy VI: Nursing Management
55
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
55
01:15Development of the Lymphatic System
1.2K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
1.2K
01:16Lymphatic Vessels and Lymph Transport
12.8K
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
12.8K
01:18Lymphoid Cells and Tissues
1.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.6K